Results 241 to 250 of about 1,661,955 (279)

Glucocorticoid-induced diabetes mellitus: mechanisms, risk factors, and clinical pathways with insights from autoimmune rheumatic diseases. [PDF]

Rheumatol Int
Soura M, Bakiri A, Fragoulis GE, Vassilakis KD.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Regenerative Cell and Tissue-based Therapies for Pulmonary Arterial Hypertension

Canadian Journal of Cardiology, 2014
Within the span of 2 decades, cell-based regenerative therapies for pulmonary arterial hypertension have progressed from bench-side hypotheses to clinical realities. Promising preclinical investigations that examined the therapeutic potential of endothelial progenitor cell and mesenchymal stem cell populations have demonstrated the safety and efficacy ...
William S, Foster, Colin M, Suen, Duncan J, Stewart   +2 more
openaire   +2 more sources

Importance of repeat tissue biopsy and tissue-based epidermal growth factor receptor T790M testing in progressed nonsmall cell lung carcinoma patients upon negative plasma genotyping for selection of third-generation tyrosine kinase inhibitor therapy: A case study

Indian Journal of Cancer, 2017
Resistance to 1st or 2nd generation epidermal growth factor receptor (EGFR) - tyrosine kinases (TKIs) develops predominantly due to an acquired mutation, EGFR T790M. Third-generation EGFR-TKIs have demonstrated potent activity against TKI resistance mediated by EGFR T790M.
R, Mistry, A, Patil
openaire   +2 more sources

Regulatory Oversight of Cell- and Tissue-Based Therapeutic Products and Gene Therapy Products in Singapore

2015
The regulatory environment for cell- and tissue-based therapeutic products and gene therapy products is rapidly evolving and drug regulatory agencies are working towards establishing a risk-based system in the regulatory framework. Similarly in Singapore, a risk-based tiered approach has been applied whereby clinical trials and product licence of high ...
Choon Wee, Goh, Srinivasan N, Kellathur, Lee Lee, Ong, Xiaofeng, Wu   +3 more
openaire   +2 more sources

Regulation Policy on Cell- and Tissue-Based Therapy Products in Korea

Tissue Engineering Part A, 2015
Extensive investment on research and development of cell therapy products (CTPs) and tissue-engineered products (TEPs) has been made in Korea, and various commercial products are born in market. The Ministry of Food and Drug Safety (MFDS) in Korea regulates CTPs and TEPs as biological products under the authority of the Pharmaceutical Affairs Act.
openaire   +2 more sources